76641-65-1 Usage
Uses
Used in Pharmaceutical Synthesis:
2,4,6,7(1H,3H)-Pteridinetetrone, 5,8-dihydro-8-(2-hydroxyethyl)-3-methylis used as a precursor in the synthesis of various pharmaceuticals and biologically active compounds. Its unique pteridine ring system and functional groups make it a valuable building block for creating new drugs with potential therapeutic properties.
Used in Research and Development:
In the field of research and development, 2,4,6,7(1H,3H)-Pteridinetetrone, 5,8-dihydro-8-(2-hydroxyethyl)-3-methylis utilized for exploring its potential therapeutic applications. Its nitrogen-containing heterocyclic structure offers opportunities for the discovery of new treatments and interventions in various medical conditions.
Used in Organic Chemistry:
2,4,6,7(1H,3H)-Pteridinetetrone, 5,8-dihydro-8-(2-hydroxyethyl)-3-methylis also employed in organic chemistry for studying the properties and reactions of heterocyclic compounds. Its unique structure allows chemists to investigate various chemical transformations and mechanisms, contributing to the understanding of organic reactions and the development of new synthetic methods.
Check Digit Verification of cas no
The CAS Registry Mumber 76641-65-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,6,6,4 and 1 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 76641-65:
(7*7)+(6*6)+(5*6)+(4*4)+(3*1)+(2*6)+(1*5)=151
151 % 10 = 1
So 76641-65-1 is a valid CAS Registry Number.
76641-65-1Relevant academic research and scientific papers
Specific enzyme inhibitors in vitamin biosynthesis. Part 3. The synthesis and inhibitory properties of some substrates and transition state analogues of riboflavin synthase
Al-Hassan, Saieba S.,Kulick, Russell J.,Livingstone, Daniel B.,Suckling, Colin J.,Wood, Hamish C. S.,Wrigglesworth, Roger,Ferone, Robert
, p. 2645 - 2656 (2007/10/02)
Syntheses of potential inhibitors of riboflavin synthase are described. The tolerance of the enzyme to bulky substituents was investigated by the synthesis of substrate analogues which included lumazines and pyrido[2,3-d]-pyrimidines prepared by condensation of α-diketones and β-keto-aldehydes respectively with appropriate amino-substituted uracils. Potential transition-state analogues, including 7-oxolumazines, 7-oxopyrido[2,3-d] pyrimidines, and 6,7-dioxolumazines were also prepared by similar condensations using α-keto-acid derivatives, dimethyl acetylenedicarboxylate, and oxalate derivatives. Two possible dual affinity inhibitors were also prepared. The potential inhibitors were tested using riboflavin synthase from yeast or from E. coli, and their effectiveness is discussed in relation to the bulk and electronic character of the substituents.
